Gedeon Richter Areas of Expertise Neuropsychiatry Cariprazine Scientific posters
Scientific posters
Neuropsychiatry Biotechnology Women's Healthcare General Medicines
32nd Annual Meeting of the European Psychiatric Association (EPA), 6-9 April 2024
Exploring cariprazine's potential in late-stage schizophrenia treatment
102 kb 11/04/2024 pdf
The role of partial agonists and specifically cariprazine in dual disorders
117 kb 11/04/2024 pdf
Relapse prevention with cariprazine in patients with early-stage schizophrenia
207 kb 11/04/2024 pdf
Predominant negative symptoms: Views of patients vs. doctors in a 1-year observational study
86 kb 11/04/2024 pdf
36th European College of Neuropsychopharmacology Congress, 7-10 October 2023
Cariprazine in female schizophrenia patients. Real world evidence from an observational study
197 kb 17/10/2023 pdf
Time course of significantly greater improvement in global illness-severity with cariprazine versus risperidone in schizophrenia patients with predominant negative symptoms
233 kb 17/10/2023 pdf
23rd World Congress of Psychiatry, 28 September-1 October 2023 
Cariprazine’s safety profile over the approved dose range
80 kb 17/10/2023 pdf
Cariprazine & clozapine. A promising combination for treatment-resistant schizophrenia
89 kb 17/10/2023 pdf
35th European College of Neuropsychopharmacology Congress, 15-18 October 2022
Time course of adverse events
112 kb 26/10/2022 PDF
Cariprazine 3mg/day in bipolar depression
133 kb 26/10/2022 PDF
The triangle of schizophrenia treatment: Dosing, Side Effects and Rescue Medication in an observational study with Cariprazine
217 kb 26/10/2022 pdf
34th European College of Neuropsychopharmacology Congress, 2-5 October 2021
Results of a Phase 1 Trial Investigating the Effect of Cariprazine on the Pharmacokinetics of a Combined Oral Contraceptive
372 kb 05/10/2021 PDF
Cariprazine’s efficacy in residual patients with schizophrenia: a post hoc analysis in a chronic patient population
168 kb 05/10/2021 PDF
World Congress of Biological Psychiatry (organized by WFSBP), 28-30 June 2021, virtual Congress
Broad Spectrum Clinical Efficacy of Cariprazine in Schizophrenia
101 kb 05/07/2021 pptx
A Post-Hoc Analysis of the Safety Profile of Cariprazine and Potential Relevance for Patient Adherence in Schizophrenia
1330 kb 05/07/2021 pptx
Efficacy of Cariprazine on Cognitive Symptom Domains in Patients with Schizophrenia and Bipolar Depression
146 kb 05/07/2021 pptx
European Congress of Psychiatry (EPA), 10-13 April 2021, virtual meeting
Safety During Polypharmacy: A Post-hoc Analysis Examining The Safety Profile Of Cariprazine With Other Antipsychotics In The Cross-Titration Phase
191 kb 09/04/2021 pdf
The effect of cariprazine on patient engagement: Post hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
274 kb 09/04/2021 pdf
Tolerability of Cariprazine in the Early Stage of Schizophrenia: A Pooled, Post-hoc Analysis of 4 Phase II/III Double-blind Placebo-controlled Trials
211 kb 09/04/2021 pdf
20th WPA World Congress of Psychiatry, 10-13 March 2021, Virtual Congress
Safety of cariprazine in the light of its receptor profile
267 kb 16/03/2021 pdf
The efficacy of cariprazine in light of its receptor profile
253 kb 16/03/2021 pdf
ECNP Psychiatry Congress,12-15 September 2020, virtual meeting
Safety with or without treatment: a post-hoc analysis comparing stable patients discontinuing cariprazine treatment versus patients taking cariprazine long-term
203 kb 15/09/2020 pdf
Efficacy of Cariprazine in the Early Stage of Schizophrenia: A Pooled, Post-hoc Analysis of 3 Phase II/III Double- blind Placebo-controlled Trials
193 kb 15/09/2020 pdf
Long-term functional improving effects of cariprazine: Post-hoc analyses of acute and predominant negative symptom schizophrenia patient data
293 kb 15/09/2020 pdf
The effect of cariprazine on agitation and hostility in patients with schizophrenia: post-hoc analysis
315 kb 15/09/2020 pdf
EPA Psychiatry Congress, 4-7 July 2020, virtual meeting
Network analysis of acute symptoms of schizophrenia
410 kb 07/07/2020 pdf
Network analysis of negative symptoms of schizophrenia in acute and in stable patients with persistent, predominantly negative symptoms
365 kb 07/07/2020 pdf
Cardiac safety with cariprazine treatment
313 kb 07/07/2020 pdf
The efficacy and safety of cariprazine in schizophrenia patients with insufficient effectiveness of previous antipsychotic therapy: A Latvian observational study
258 kb 07/07/2020 pdf
Efficacy of cariprazine in the treatment of acute and primary negative symptoms of schizophrenia: posthoc analyses versus risperidone
289 kb 07/07/2020 pdf
EPA Psychiatry Congress, 6-9 April 2019, Warsaw, Poland‎
Akathisia during cariprazine treatment: Post-hoc analyses of pooled schizophrenia studies
389 kb 05/11/2020 pdf
Clinical improvement of patients with predominant negative symptoms of schizophrenia: post-hoc analysis of cariprazine versus risperidone
434 kb 05/11/2020 pdf
Correlation analysis of symptomatic and functional improvements of patients with predominant negative symptom of schizophrenia
180 kb 05/11/2020 pdf
World Congress of Biological Psychiatry (organized by WFSBP), 28-30 June 2021, virtual Congress
Hormonal Effects of Cariprazine: Post Hoc Analysis of Pooled Data from Schizophrenia Studies for Sexual Dysfunction and Prolactin Changes
231 kb 05/11/2020 pdf
Efficacy of Cariprazine in Predominant Negative Symptomps of Schizophrenia - Post Hoc Analyses Against Different Comparators
260 kb 05/11/2020 pdf
Improvement of Schizophrenia Social Amotivation and Expressive Deficits Over Time After Cariprazine and Risperidone Treatment: Post Hoc Analysis of a Phase-3 Trial
342 kb 05/11/2020 pdf